Literature DB >> 15143334

Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study.

Akishi Ooi1, Takuo Takehana, Xiaoling Li, Shioto Suzuki, Kazuyoshi Kunitomo, Hiroshi Iino, Hideki Fujii, Yasuhisa Takeda, Yoh Dobashi.   

Abstract

Overexpression of HER-2 and the epidermal growth factor receptor (EGFR) has been observed in many cancers, sometimes accompanied by gene amplification. To assess whether novel chemotherapies targeting these overexpressed proteins may be effective for the treatment of colorectal cancers, we examined the exact frequency of HER-2 and EGFR overexpression, the relationship between gene amplification and protein expression, and the heterogeneity of gene amplification within and between primary and metastatic tumors. We evaluated 244 colorectal cancers immunohistochemically. All tumors found to overexpress HER-2 or EGFR were further analyzed for gene amplification by fluorescent in situ DNA hybridization. Overexpression of HER-2 and EGFR was found in 8 (3%) and 19 (8%) of the 244 colorectal carcinomas, respectively. Gene amplification was observed in 100 and 58% of the tumors exhibiting HER-2 and EGFR overexpression, respectively. HER-2 amplification in cancer cells was characterized by clusters of hybridization signals, suggesting amplicons in homogeneously staining regions that were predominant in most primary and metastatic tumors. EGFR amplification, observed as scattered signals reminiscent of amplicons in double minute chromosomes, or coamplification of EGFR with the centromeric regions was observed as a minor population within primary tumors, and found in variety of populations in metastatic tumors. Overexpression of HER-2 and EGFR were observed in only a small fraction of colorectal carcinomas, but were frequently accompanied by gene amplification.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15143334     DOI: 10.1038/modpathol.3800137

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  56 in total

1.  KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer.

Authors:  Marta Herreros-Villanueva; Maximiliano Rodrigo; Manuel Claver; Pilar Muñiz; Enrique Lastra; Carlos García-Girón; Maria Jesus Coma del Corral
Journal:  Mol Biol Rep       Date:  2010-06-20       Impact factor: 2.316

Review 2.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

3.  Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.

Authors:  Yu Sunakawa; Dongyun Yang; Miriana Moran; Stephanie H Astrow; Akihito Tsuji; Craig Stephens; Wu Zhang; Shu Cao; Takehiro Takahashi; Tadamichi Denda; Ken Shimada; Mitsugu Kochi; Masato Nakamura; Masahito Kotaka; Yoshihiko Segawa; Toshiki Masuishi; Masahiro Takeuchi; Masashi Fujii; Toshifusa Nakajima; Wataru Ichikawa; Heinz-Josef Lenz
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

4.  Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas.

Authors:  Zhangjuan Song; Yan Deng; Kangmin Zhuang; Aimin Li; Side Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 5.  Update on Sporadic Colorectal Cancer Genetics.

Authors:  Karin M Hardiman
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

6.  Epidermal growth factor receptor status in anaplastic thyroid carcinoma.

Authors:  Dae Ho Lee; Geon Kook Lee; Sun-Young Kong; Myoung Chul Kook; Sun Kyung Yang; So Yeon Park; Seong Hoe Park; Bhumsuk Keam; Do Joon Park; Bo Youn Cho; Seok Won Kim; Ki-Wook Chung; Eun Sook Lee; Sun Wook Kim
Journal:  J Clin Pathol       Date:  2006-11-01       Impact factor: 3.411

7.  EGFR and HER2 expression in advanced biliary tract cancer.

Authors:  Jan Harder; Oliver Waiz; Florian Otto; Michael Geissler; Manfred Olschewski; Brigitte Weinhold; Hubert E Blum; Annette Schmitt-Graeff; Oliver G Opitz
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

8.  Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma.

Authors:  M Watanabe; K Kono; Y Kawaguchi; Y Mizukami; K Mimura; T Maruyama; H Fujii
Journal:  Br J Cancer       Date:  2009-12-22       Impact factor: 7.640

9.  Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study.

Authors:  Ricardo S Macarenco; Timothy S Uphoff; Heather Flynn Gilmer; Robert B Jenkins; Stephen N Thibodeau; Jean E Lewis; Julian R Molina; Ping Yang; Marie-Christine Aubry
Journal:  Mod Pathol       Date:  2008-06-27       Impact factor: 7.842

10.  Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.

Authors:  Ann Marie Egloff; Jennifer Rubin Grandis
Journal:  J Oncol       Date:  2009-07-14       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.